Yi JH - Search Results

1

Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib.

Maeng CH, Yi JH, Lee J, Hong JY, Choi MK, Jung HA, Park JO, Park SH, Park YS, Kang WK, Lim HY. Maeng CH, et al. Among authors: yi jh. Anticancer Res. 2013 Oct;33(10):4619-26. Anticancer Res. 2013. PMID: 24123039

2

Extraosseous osteosarcoma: single institutional experience in Korea.

Lee S, Lee MR, Lee SJ, Ahn HK, Yi J, Yi SY, Seo SW, Sung KS, Park JO, Lee J. Lee S, et al. Asia Pac J Clin Oncol. 2010 Jun;6(2):126-9. doi: 10.1111/j.1743-7563.2010.01278.x. Asia Pac J Clin Oncol. 2010. PMID: 20565425

3

Clinical presentation of carcinoma of unknown primary: 14 years of experience.

Yi JH, La Choi Y, Lee SJ, Ahn HK, Baek KK, Lim T, Lee DJ, Han BR, Lee HY, Jun HJ, Lee J, Park YH. Yi JH, et al. Tumour Biol. 2011 Feb;32(1):45-51. doi: 10.1007/s13277-010-0089-6. Epub 2010 Aug 10. Tumour Biol. 2011. PMID: 20697986

4

Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia.

Yi JH, Yi SY, Lee HR, Lee SI, Lim DH, Kim JH, Park KW, Lee J. Yi JH, et al. Among authors: yi sy. Melanoma Res. 2011 Jun;21(3):223-7. doi: 10.1097/CMR.0b013e3283457743. Melanoma Res. 2011. PMID: 21471822

5

A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer.

Yi JH, Lee J, Park SH, Lee KT, Lee JK, Lee KH, Choi DW, Choi SH, Heo JS, Lim DH, Park YS, Lim HY, Kang WK, Park K, Park JO. Yi JH, et al. Oncology. 2011;80(3-4):175-80. doi: 10.1159/000328449. Epub 2011 Jun 24. Oncology. 2011. PMID: 21701231

6

Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.

Kim ST, Lim DH, Jang KT, Lim T, Lee J, Choi YL, Jang HL, Yi JH, Baek KK, Park SH, Park YS, Lim HY, Kang WK, Park JO. Kim ST, et al. Among authors: yi jh. Mol Cancer Ther. 2011 Oct;10(10):1993-9. doi: 10.1158/1535-7163.MCT-11-0269. Epub 2011 Aug 23. Mol Cancer Ther. 2011. PMID: 21862683 Clinical Trial.

7

A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study.

Yi JH, Thongprasert S, Lee J, Doval DC, Park SH, Park JO, Park YS, Kang WK, Lim HY. Yi JH, et al. Eur J Cancer. 2012 Jan;48(2):196-201. doi: 10.1016/j.ejca.2011.11.017. Epub 2011 Dec 14. Eur J Cancer. 2012. PMID: 22176869 Clinical Trial.

8

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.

Yi JH, Lee J, Lee J, Park SH, Park JO, Yim DS, Park YS, Lim HY, Kang WK. Yi JH, et al. Br J Cancer. 2012 Apr 24;106(9):1469-74. doi: 10.1038/bjc.2012.100. Epub 2012 Mar 29. Br J Cancer. 2012. PMID: 22460270 Free PMC article. Clinical Trial.

9

Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine.

Woo HI, Kim KK, Choi H, Kim S, Jang KT, Yi JH, Park YS, Park JO, Lee SY. Woo HI, et al. Among authors: yi jh. Pharmacogenomics. 2012 Jul;13(9):1023-35. doi: 10.2217/pgs.12.82. Pharmacogenomics. 2012. PMID: 22838950

10

Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.

Yi JH, Huh J, Kim HJ, Kim SH, Kim SH, Kim KH, Do YR, Mun YC, Kim H, Kim MK, Kim HJ, Kim T, Kim DD. Yi JH, et al. Ann Hematol. 2013 Apr;92(4):459-69. doi: 10.1007/s00277-012-1635-7. Epub 2012 Dec 23. Ann Hematol. 2013. PMID: 23262795

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

397 results

Search Page

Filters